Overview

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the response rate of decitabine in previously treated and untreated Taiwanese participants with Myelodysplastic Syndrome (MDS - a disease associated with decreased production of blood cells, blood cells are produced but do not mature normally).
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Taiwan Ltd
Treatments:
Azacitidine
Decitabine